3-Year clinical outcomes in the randomized sort out III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents

JACC: Cardiovascular Interventions

Volumn 5, Issue 8, 2012, Pages 812-818

  Maeng, Michael ^a   Tilsted, Hans Henrik ^b   Jensen, Lisette Okkels ^c   Kaltoft, Anne ^a   Kelbæk, Henning ^d   Abildgaard, Ulrik ^a   Villadsen, Anton B ^b   Krusell, Lars Romer ^a   Ravkilde, Jan ^b   Hansen, Knud Nørregaard ^c   Christiansen, Evald Høj ^a   Aarøe, Jens ^b   Jensen, Jan Skov ^a   Kristensen, Steen Dalby ^a   Bøtker, Hans Erik ^a   Madsen, Morten ^e   Thayssen, Per ^c   Sørensen, Henrik Toft ^e   Thuesen, Leif ^a   Lassen, Jens Flensted ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

coronary; drug eluting; randomized clinical trial; sirolimus; stent; zotarolimus

Indexed keywords

RAPAMYCIN; ZOTAROLIMUS;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; SAFETY; SIROLIMUS ELUTING STENT; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION; TREATMENT OUTCOME; ZOTAROLIMUS ELUTING STENT;

CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865309452     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2012.04.008     Document Type: Article

References (18)

1. J.W. Moses, M.B. Leon, J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323 (Pubitemid 37186209)
2. H. Kelbaek, L. Kløvgaard, S. Helqvist Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial J Am Coll Cardiol 51 2008 2011 2016 (Pubitemid 351689054)
3. G.W. Stone, S.G. Ellis, D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231 (Pubitemid 38067635)
4. L.O. Jensen, H.H. Tilsted, P. Thayssen Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes From the Western Denmark Heart Registry EuroIntervention 5 2010 898 905
5. K. Rasmussen, M. Maeng, A. Kaltoft Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
6. D.W. Park, Y.H. Kim, S.C. Yun Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and Paclitaxel-Eluting Stent for Coronary Lesions) randomized trial J Am Coll Cardiol 56 2010 1187 1195
7. M.B. Leon, D.E. Kandzari, E.L. Eisenstein Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 2 2009 1208 1218
8. R.A. Byrne, A. Kastrati, K. Tiroch 2-Year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents J Am Coll Cardiol 55 2010 2536 2543
9. A. Kaltoft, L.O. Jensen, M. Maeng Two-year clinical outcomes after implantation of coronary sirolimus- and paclitaxel-eluting stents and bare metal stents in Western Denmark J Am Coll Cardiol 53 2008 658 664
10. D.E. Kandzari, L. Mauri, J.J. Popma Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents: 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 4 2011 543 550
11. G. Nakazawa, A.V. Finn, M.C. John, F.D. Kolodgie, R. Virmani The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents Am J Cardiol 100 2007 36M 44M
12. M. Joner, A.V. Finn, A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202 (Pubitemid 43929240)
13. G. Nakazawa, A.V. Finn, M. Vorpahl, E.R. Ladich, F.D. Kolodgie, R. Virmani Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents J Am Coll Cardiol 57 2011 390 398
14. A. Miyazawa, J. Ako, Y. Hongo Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III Am Heart J 155 2008 108 113 (Pubitemid 350234763)
15. R. Sakurai, Y. Hongo, M. Yamasaki Detailed intravascular ultrasound analysis of zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial) Am J Cardiol 100 2007 818 823
16. C. Kaiser, S. Galatius, P. Erne Drug-eluting versus bare-metal stents in large coronary arteries N Engl J Med 363 2010 2310 2319
17. S. Silber, S. Windecker, P. Vranckx, P.W. Serruys RESOLUTE All Comers investigators Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247
18. G.G. Stefanini, B. Kalesan, P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948